查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
多發性骨髓瘤市場 - 全球規模、佔有率、趨勢分析、機會、預測報告，2019-2029
市場調查報告書
商品編碼
1364730

多發性骨髓瘤市場 - 全球規模、佔有率、趨勢分析、機會、預測報告，2019-2029

Multiple Myeloma Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Treatment ; By Diagnosis ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球多發性骨髓瘤市場規模將以5.39%的複合年複合成長率穩定成長，到2029年將達到294億美元。

由於全球對多發性骨髓瘤治療和管理的興趣日益濃厚以及標靶藥物的快速發展，全球多發性骨髓瘤市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的研究中估計，2022 年全球多發性骨髓瘤市場規模為 214.6 億美元。 BlueWeave預測，在2023年至2029年的預測期內，全球多發性骨髓瘤市場規模將以5.39%的年複合成長率成長，到2029年將達到294億美元。全球多發性骨髓瘤市場的主要成長促進因素包括擴大採用 microRNA 療法。這些創新治療方法利用 microRNA 的潛力來控制基因表現並監督不同的細胞過程。精確標靶化microRNA治療方法的進步有望為多發性骨髓瘤提供更個體化和精確的治療方法。此外，先進醫學平台的興起在推動多發性骨髓瘤市場的擴張方面發揮關鍵作用。這些多層面的平台涵蓋廣泛的技術和方法，有助於了解疾病的分子基礎、鑒定新的治療標靶以及開發更有效的治療方法。透過利用這些複雜平台的力量，研究人員和醫療保健專業人員可以更深入地研究多發性骨髓瘤的複雜性，並推動突破性治療性介入。然而，高昂的處理成本和嚴格的法規要求預計將限制預測期內的整體市場成長。

該報告的詳細分析提供了有關全球多發性骨髓瘤市場的成長潛力、未來趨勢和統計數據的資訊。它還揭示了推動市場總規模預測的要素。該報告承諾提供全球多發性骨髓瘤市場的最新技術趨勢和產業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球多發性骨髓瘤市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 成長促進因素
      • 全球多發性骨髓瘤發生率增加
      • 分子標靶藥物的進展
    • 抑制因素
      • 昂貴的治療費用
      • 嚴格的法規要求
    • 機會
      • 新興市場
      • 個人化醫療
    • 任務
      • 競爭
      • 抗藥性
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球多發性骨髓瘤市場概述

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 冒煙（緩慢進行性）多發性骨髓瘤
      • 活動性（有症狀）多發性骨髓瘤
    • 透過治療
      • 化療
      • 標靶治療
      • 免疫調節劑
      • 類固醇
      • 改變骨骼的藥物
      • 免疫療法
      • 骨髓/幹細胞移植
      • 放射治療
      • 外科手術
      • 其他
    • 透過診斷
      • 血液和尿液檢查
      • X光
      • 磁振造影(MRI)
      • 電腦斷層掃描（CT 或 CAT）掃描
      • 正子斷層掃描 (PET) 或 PET-CT 掃描
      • 骨髓抽吸和切片檢查
      • 抽脂手術
      • 腫瘤生物標記檢測
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美多發性骨髓瘤市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 透過診斷
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲多發性骨髓瘤市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 透過診斷
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太多發性骨髓瘤市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 透過診斷
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他國家

第8章 拉丁美洲多發性骨髓瘤市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 透過診斷
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 拉丁美洲其他地區

第9章 中東及非洲多發性骨髓瘤市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 透過診斷
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭形勢

  • 主要企業及其產品列表
  • 2022 年多發性骨髓瘤全球市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章COVID-19 對全球多發性骨髓瘤市場的影響

12：公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人員、主要競爭、聯絡地址、策略展望、SWOT分析）

  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • ONO Pharmaceutical Co., Ltd
  • Takeda Pharmaceutical Company Ltd
  • Roche Group
  • 其他主要企業

第13章關鍵戰略建議

第14章調查方法

簡介目錄
Product Code: BWC23812

Global Multiple Myeloma Market Size Grows at Steady CAGR of 5.39% to Reach USD 29.4 Billion by 2029.

Global multiple myeloma market is flourishing because of the growing focus on the treatment and management of increasing incidences of multiple myeloma globally and rapid advancements in targeted drugs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global multiple myeloma market size at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global multiple myeloma market size to grow at a significant CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include the increasing adoption of microRNA therapies. These innovative treatment modalities harness the potential of microRNAs to regulate gene expression and oversee diverse cellular processes. The evolution of precisely targeted microRNA therapies holds promise for delivering more individualized and accurate treatments for multiple myeloma. Furthermore, the ascent of advanced biomedicine platforms plays a pivotal role in propelling the expansion of the multiple myeloma market. These multifaceted platforms encompass a wide spectrum of technologies and methodologies that facilitate the understanding of the molecular foundations of the disease, the identification of novel therapeutic targets, and the development of more effective treatment approaches. By harnessing the capabilities of these sophisticated platforms, researchers and healthcare professionals can delve deeper into the intricacies of multiple myeloma, thereby advancing the creation of groundbreaking therapeutic interventions. However, high treatment costs and stringent regulatory requirements are anticipated to restrain the overall market growth during the forecast period.

Global Multiple Myeloma Market - Overview:

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The Global Multiple Myeloma Market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market - By Treatment

Based on treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery segments. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs, such as Thalomid, Revlimid, and pomalyst, being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Competitive Landscape:

Major players operating in the global multiple myeloma market include: Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Multiple Myeloma Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Multiple Myeloma Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Multiple Myeloma Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. The rising incidence of Multiple Myeloma globally
      • 3.2.1.2. Advancements in targeted drugs
    • 3.2.2. Restraints
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Stringent regulatory requirements
    • 3.2.3. Opportunities
      • 3.2.3.1. Emerging markets
      • 3.2.3.2. Personalized medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Competition
      • 3.2.4.2. Drug resistance
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Multiple Myeloma Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Smoldering (indolent) Multiple Myeloma
      • 4.2.1.2. Active (symptomatic) Multiple Myeloma
    • 4.2.2. By Treatment
      • 4.2.2.1. Chemotherapy
      • 4.2.2.2. Targeted Therapy
      • 4.2.2.3. Immunomodulatory Drugs
      • 4.2.2.4. Steroids
      • 4.2.2.5. Bone-modifying Drugs
      • 4.2.2.6. Immunotherapy
      • 4.2.2.7. Bone Marrow/Stem Cell Transplantation
      • 4.2.2.8. Radiation Therapy
      • 4.2.2.9. Surgery
      • 4.2.2.10. Others
    • 4.2.3. By Diagnosis
      • 4.2.3.1. Blood & Urine Tests
      • 4.2.3.2. X-ray
      • 4.2.3.3. Magnetic Resonance Imaging (MRI)
      • 4.2.3.4. Computed Tomography (CT or CAT) Scan
      • 4.2.3.5. Positron Emission Tomography (PET) or PET-CT Scan
      • 4.2.3.6. Bone Marrow Aspiration and Biopsy
      • 4.2.3.7. Fat Pad Aspirate
      • 4.2.3.8. Biomarker Testing of the Tumor
      • 4.2.3.9. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Multiple Myeloma Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment
    • 5.2.3. By Diagnosis
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Treatment
      • 5.2.4.1.3. By Diagnosis
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Treatment
      • 5.2.4.2.3. By Diagnosis

6. Europe Multiple Myeloma Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Diagnosis
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Treatment
      • 6.2.4.1.3. By Diagnosis
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Treatment
      • 6.2.4.2.3. By Diagnosis
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Treatment
      • 6.2.4.3.3. By Diagnosis
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Treatment
      • 6.2.4.4.3. By Diagnosis
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Treatment
      • 6.2.4.5.3. By Diagnosis
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Treatment
      • 6.2.4.6.3. By Diagnosis
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Treatment
      • 6.2.4.7.3. By Diagnosis
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Type
      • 6.2.4.8.2. By Treatment
      • 6.2.4.8.3. By Diagnosis
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Type
      • 6.2.4.9.2. By Treatment
      • 6.2.4.9.3. By Diagnosis

7. Asia-Pacific Multiple Myeloma Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Diagnosis
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Treatment
      • 7.2.4.1.3. By Diagnosis
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Treatment
      • 7.2.4.2.3. By Diagnosis
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Treatment
      • 7.2.4.3.3. By Diagnosis
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Treatment
      • 7.2.4.4.3. By Diagnosis
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Treatment
      • 7.2.4.5.3. By Diagnosis
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Treatment
      • 7.2.4.6.3. By Diagnosis
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Treatment
      • 7.2.4.7.3. By Diagnosis
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Treatment
      • 7.2.4.8.3. By Diagnosis
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Treatment
      • 7.2.4.9.3. By Diagnosis
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Treatment
      • 7.2.4.10.3. By Diagnosis

8. Latin America Multiple Myeloma Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Diagnosis
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Treatment
      • 8.2.4.1.3. By Diagnosis
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Treatment
      • 8.2.4.2.3. By Diagnosis
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Treatment
      • 8.2.4.3.3. By Diagnosis
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Treatment
      • 8.2.4.4.3. By Diagnosis
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Treatment
      • 8.2.4.5.3. By Diagnosis

9. Middle East & Africa Multiple Myeloma Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Treatment
      • 9.2.4.1.3. By Diagnosis
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Treatment
      • 9.2.4.2.3. By Diagnosis
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Treatment
      • 9.2.4.3.3. By Diagnosis
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Treatment
      • 9.2.4.4.3. By Diagnosis
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Treatment
      • 9.2.4.5.3. By Diagnosis
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Treatment
      • 9.2.4.6.3. By Diagnosis
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Treatment
      • 9.2.4.7.3. By Diagnosis
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Treatment
      • 9.2.4.8.3. By Diagnosis

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Multiple Myeloma Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Multiple Myeloma Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Sanofi
  • 12.2. Pfizer Inc.
  • 12.3. GlaxoSmithKline plc
  • 12.4. Novartis AG
  • 12.5. Bayer AG
  • 12.6. Eli Lilly and Company
  • 12.7. Merck & Co., Inc.
  • 12.8. AstraZeneca
  • 12.9. Bristol-Myers Squibb Company
  • 12.10. AbbVie Inc.
  • 12.11. Teva Pharmaceutical Industries Ltd
  • 12.12. ONO Pharmaceutical Co., Ltd
  • 12.13. Takeda Pharmaceutical Company Ltd
  • 12.14. Roche Group
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations